Page last updated: 2024-10-30

losartan and Hyperlipemia

losartan has been researched along with Hyperlipemia in 14 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone."7.81Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015)
"Combination of pioglitazone and losartan is more effective in reducing renal injury-induced atherosclerosis than either treatment alone."3.81Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. ( Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y, 2015)
" MASSIVE PROTEINURIA: An angiotensin II inhibitor, losartan, has been found to be effective against massive proteinuria (> 3."3.71[Complications in kidney transplantation]. ( Ouali, N, 2001)
" It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes."3.70Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000)
"Hemodialysis patients have uremic dyslipidemia, represented by elevated serum intermediate-density lipoprotein cholesterol (IDL-C) levels, and an increased cardiovascular mortality rate."2.71Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. ( Furukawa, T; Hayashi, M; Homma, K; Ichihara, A; Kaneshiro, Y; Kanno, Y; Saruta, T; Takemitsu, T; Takenaka, T; Yoshizawa, M, 2005)
"Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important."2.44[Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008)
"We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor."1.35Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008)
"Captopril was more effective than losartan in preserving of nitric oxide."1.34[Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits]. ( Antelava, NA; Gogolauri, MI; Gongadze, NV; Kezeli, TD; Pachkoriia, KZ, 2007)
" Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age."1.29Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. ( Baba, N; Sakemi, T, 1993)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's11 (78.57)29.6817
2010's1 (7.14)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Elseweidy, MM1
Elnagar, GM1
M Elsawy, M1
Ali, AA1
Zein, N1
Yamamoto, S1
Zhong, J1
Yancey, PG1
Zuo, Y1
Linton, MF1
Fazio, S1
Yang, H1
Narita, I1
Kon, V1
Chan, EC1
Jones, GT1
Dusting, GJ1
Datla, SR1
Jiang, F1
Diener, HC1
el-Batran, SA1
el-Shenawy, SM1
Nofal, SM1
Abdel-Salam, OM1
Arbid, MS1
Ichihara, A1
Hayashi, M1
Kaneshiro, Y1
Takemitsu, T1
Homma, K1
Kanno, Y1
Yoshizawa, M1
Furukawa, T1
Takenaka, T1
Saruta, T1
Vogt, L1
Laverman, GD1
van Tol, A1
Groen, AK1
Navis, G1
Dullaart, RP1
Antelava, NA1
Gongadze, NV1
Gogolauri, MI1
Kezeli, TD1
Pachkoriia, KZ1
Ogino, K1
Igawa, O1
Hisatome, I1
Imanishi, T1
Kuroi, A1
Ikejima, H1
Kobayashi, K1
Muragaki, Y1
Mochizuki, S1
Goto, M1
Yoshida, K1
Akasaka, T1
Sakemi, T1
Baba, N1
Milionis, HJ1
Elisaf, MS1
Chen, HJ1
Li, DY1
Saldeen, T1
Phillips, MI1
Mehta, JL1
Ouali, N1

Reviews

1 review available for losartan and Hyperlipemia

ArticleYear
[Other antihyperuricemic agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:4

    Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout

2008

Trials

1 trial available for losartan and Hyperlipemia

ArticleYear
Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:5

    Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blo

2005

Other Studies

12 other studies available for losartan and Hyperlipemia

ArticleYear
Losartan and azelastine either alone or in combination as modulators for endothelial dysfunction and platelets activation in diabetic hyperlipidemic rats.
    The Journal of pharmacy and pharmacology, 2020, Volume: 72, Issue:12

    Topics: Alloxan; Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Blood Platelets; Diabete

2020
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
    Atherosclerosis, 2015, Volume: 242, Issue:1

    Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atheroscle

2015
Prevention of aortic elastic lamina defects by losartan in apolipoprotein(E)-deficient mouse.
    Clinical and experimental pharmacology & physiology, 2009, Volume: 36, Issue:9

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Aortic Diseas

2009
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic

2003
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats.
    Pharmacological research, 2004, Volume: 50, Issue:2

    Topics: Alloxan; Animals; Blood Glucose; Blood Proteins; Carbamates; Cholesterol, LDL; Diabetes Mellitus, Ex

2004
Cellular cholesterol efflux to plasma from proteinuric patients is elevated and remains unaffected by antiproteinuric treatment.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:1

    Topics: Adult; Analysis of Variance; Apolipoproteins; Biological Transport; Case-Control Studies; Cholestero

2006
[Comparative characteristic of angiotensin-converting enzyme inhibitor--captopril and the angiotensin II receptor blokers--losartan action on the oxidative metabolism in experimental hyperlipidemia in rabbits].
    Georgian medical news, 2007, Issue:150

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopri

2007
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:3

    Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An

2008
Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats.
    Nephron, 1993, Volume: 65, Issue:3

    Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen;

1993
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
    Current medical research and opinion, 2000, Volume: 16, Issue:3

    Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans

2000
Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits.
    Biochemical and biophysical research communications, 2001, Mar-30, Volume: 282, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta; Arteriosclerosis; Chemokine CCL2;

2001
[Complications in kidney transplantation].
    Presse medicale (Paris, France : 1983), 2001, Sep-01, Volume: 30, Issue:24 Pt 2

    Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Graft Rejection; Humans; H

2001